•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
On April 23, 2026, Vinapharm Joint Stock Company (DVN) held its 2026 Annual General Meeting of Shareholders to present 2025 business results and outline its strategy for 2026–2030.
Based on consolidated financial statements, Vinapharm reported pre-tax profit of VND 825 billion in 2025. This figure represented a 62% year-on-year increase and was 77% above the company’s plan, marking the highest level since Vinapharm’s establishment.
From 2021 to 2025, the compound annual growth rate (CAGR) of pre-tax profit was about 37% per year.
During the 2021–2025 period, one milestone highlighted by Vinapharm was increasing its ownership in Sanofi Vietnam from 15% to 30%.
The AGM approved a cash dividend payout for 2025 of 10%.
Vinapharm said it is positioning itself to pioneer implementation of the national pharmaceutical-sector strategy through 2030. In 2025, Vinapharm and its subsidiary CPC1 signed an exclusive distribution agreement with Celltrion to bring biotech medicines to the Vietnamese market.
In addition, a memorandum of understanding with Promomed – Russia’s Federation on commercialization and core technology transfer was described as laying the groundwork for domestic production of biologics.
At the AGM, leadership discussed international cooperation, technology transfer, the efficiency of strategic investments, and a roadmap for listing on the Ho Chi Minh City Stock Exchange (HOSE).
For the 2026–2031 period, Vinapharm set a “dual pillar” strategy focused on strengthening internal capabilities and accelerating integration.
In governance terms, the company pledged to modernize comprehensively through ERP Oracle NetSuite and to integrate ESG standards into operations, with the aim of attracting international strategic investors and preparing for a potential HOSE listing.
The AGM elected Mr. Nguyen The Ngan as Chairman of the Board and reappointed Ms. Hàn Thị Khánh Vinh as CEO.
Vinapharm said the new board is expected to support its strategic objectives, including mastering technology to manufacture high-quality medicines, expanding domestic distribution market share, and positioning Vietnam as a regional center for producing high-value medicines.
At the close of trading on April 23, Vinapharm’s DVN shares traded at VND 20,500 per share.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
